ROCKVILLE, Md., Aug. 6, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Lewis (Lew) Barrett joined the Company as its Senior Vice President, Commercial Strategy. Mr. Barrett, former Assistant Vice President, Established Products at Pfizer and Vice President Global Business Manager, Infectious Diseases at Wyeth Pharmaceuticals, brings his expertise in the development, commercialization and launch of infectious disease product candidates to the Synthetic Biologics' team.
As the senior marketing executive, Mr. Barrett successfully led, co-chaired or served on teams that focused on infectious diseases, oncology, transplantation, and hemophilia during his 25-year career at Wyeth (acquired by Pfizer in 2009). He brings to Synthetic Biologics his expertise in U.S. and global strategy, branding, clinical development, medical affairs, supply chain, business development and strategic alliance management. Mr. Barrett was instrumental in building the brand and led global commercialization efforts for Wyeth's in-line IV antibiotic, Zosyn®/Tazocin® (the second IV antibiotic to achieve $1 billion+ in sales), and managed the U.S. launch of Wyeth's broad-spectrum IV antibiotic, Tygacil®.
Prior to joining Synthetic Biologics as Senior Vice President, Commercial Strategy, Mr. Barrett served as an advisor to the Company since September 2012. Utilizing his depth of experience in the anti-infective, hospital and biopharma fields, Mr. Barrett provides strategic consultation to the global life sciences field with a particular focus on brand strategy, lifecycle strategy, business development, and strategic communications through LL Barrett Biopharmaceutical Consulting, LLC.
Mr. Barrett earned an M.B.A. from Temple University and a B.S. degree in Biology from S
|SOURCE Synthetic Biologics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved